Search

Your search keyword '"Alekseev Boris"' showing total 434 results
Start Over Author "Alekseev Boris"
434 results on '"Alekseev Boris"'

151. Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Author

Fizazi, Karim, primary, Feyerabend, Susan, additional, Matsubara, Nobuaki, additional, Ozguroglu, Mustafa, additional, Fein, Luis Enrique, additional, Rodríguez Antolín, Alfredo, additional, Alekseev, Boris Yakovlevich, additional, Sulur, Giri, additional, Protheroe, Andrew, additional, De Porre, Peter, additional, Li, Susan, additional, Park, Youn C., additional, Mundle, Suneel, additional, Tran, Namphuong, additional, and Chi, Kim N., additional

Published
2018
Full Text
View/download PDF

152. Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Author

Clarke, Noel, primary, Wiechno, Pawel J., additional, Alekseev, Boris, additional, Sala, Nuria, additional, Jones, Robert, additional, Kocak, Ivo, additional, Chiuri, Vincenzo Emanuele, additional, Jassem, Jacek, additional, Flechon, Aude, additional, Redfern, Charles, additional, Goessl, Carsten Dietrich, additional, Burgents, Joseph, additional, Kozarski, Robert, additional, Hodgson, Darren R., additional, and Saad, Fred, additional

Published
2018
Full Text
View/download PDF

154. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

Author

Motzer, Robert J., primary, Powles, Thomas, additional, Atkins, Michael B., additional, Escudier, Bernard, additional, McDermott, David F., additional, Suarez, Cristina, additional, Bracarda, Sergio, additional, Stadler, Walter Michael, additional, Donskov, Frede, additional, Lee, Jae-Lyun, additional, Hawkins, Robert E., additional, Ravaud, Alain, additional, Alekseev, Boris Y., additional, Staehler, Michael D., additional, Uemura, Motohide, additional, Donaldson, Francis, additional, Li, Shi, additional, Huseni, Mahrukh A., additional, Schiff, Christina, additional, and Rini, Brian I., additional

Published
2018
Full Text
View/download PDF

155. HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer

Author

Pudova, Elena A., primary, Kudryavtseva, Anna V., additional, Fedorova, Maria S., additional, Zaretsky, Andrew R., additional, Shcherbo, Dmitry S., additional, Lukyanova, Elena N., additional, Popov, Anatoly Y., additional, Sadritdinova, Asiya F., additional, Abramov, Ivan S., additional, Kharitonov, Sergey L., additional, Krasnov, George S., additional, Klimina, Kseniya M., additional, Koroban, Nadezhda V., additional, Volchenko, Nadezhda N., additional, Nyushko, Kirill M., additional, Melnikova, Nataliya V., additional, Chernichenko, Maria A., additional, Sidorov, Dmitry V., additional, Alekseev, Boris Y., additional, Kiseleva, Marina V., additional, Kaprin, Andrey D., additional, Dmitriev, Alexey A., additional, and Snezhkina, Anastasiya V., additional

Published
2018
Full Text
View/download PDF

156. Final Analysis of LATITUDE, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer

Author

Fizazi, Karim, primary, Tran, NamPhuong, additional, Fein, Luis, additional, Matsubara, Nobuaki, additional, Rodriguez-Antolin, Alfredo, additional, Alekseev, Boris Y., additional, Ye, Dingwei, additional, Feyerabend, Susan, additional, Protheroe, Andrew, additional, Sulur, Giri, additional, Luna, Yesenia, additional, Li, Susan, additional, Mundle, Suneel, additional, and Chi, Kim N., additional

Published
2018
Full Text
View/download PDF

157. Upregulation of NETO2 gene in colorectal cancer

Author

Fedorova, Maria S., primary, Snezhkina, Anastasiya V., additional, Pudova, Elena A., additional, Abramov, Ivan S., additional, Lipatova, Anastasiya V., additional, Kharitonov, Sergey L., additional, Sadritdinova, Asiya F., additional, Nyushko, Kirill M., additional, Klimina, Kseniya M., additional, Belyakov, Mikhail M., additional, Slavnova, Elena N., additional, Melnikova, Nataliya V., additional, Chernichenko, Maria A., additional, Sidorov, Dmitry V., additional, Kiseleva, Marina V., additional, Kaprin, Andrey D., additional, Alekseev, Boris Y., additional, Dmitriev, Alexey A., additional, and Kudryavtseva, Anna V., additional

Published
2017
Full Text
View/download PDF

158. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C, Todd, Mary B, Chi, Kim N, LATITUDE Investigators, D'Hondt, Lionel, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, De Porre, Peter, Kheoh, Thian, Park, Youn C, Todd, Mary B, Chi, Kim N, LATITUDE Investigators, and D'Hondt, Lionel

Abstract

Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival. After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median overall survival was significantly longer in the abiraterone group than in the placebo group (not reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P<0.001). The median length of radiographic progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). Significantly better outcomes in all secondary end points were observed in the abiraterone group, including the time until pain progression, next subsequent therapy for prostate cancer, initiation of chemotherapy, and prostate-specific antigen progression (P<0.001 for all comparisons), along with next symptomatic skeletal events (P=0.009). These findings led to the unanimous recommendation by the independent data and safety monitoring committee that the trial be unblinded and crossover be allowed for patients in the placebo group to receive abiraterone. Rates of grade 3 hypertension and hypokalemia were higher in the abiraterone group. The addition of abiraterone a

Published
2017

159. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial

Author

Beer, Tomasz M, primary, Hotte, Sebastien J, additional, Saad, Fred, additional, Alekseev, Boris, additional, Matveev, Vsevolod, additional, Fléchon, Aude, additional, Gravis, Gwenaelle, additional, Joly, Florence, additional, Chi, Kim N, additional, Malik, Zafar, additional, Blumenstein, Brent, additional, Stewart, Patricia S, additional, Jacobs, Cindy A, additional, and Fizazi, Karim, additional

Published
2017
Full Text
View/download PDF

160. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Petrylak, Daniel P, primary, de Wit, Ronald, additional, Chi, Kim N, additional, Drakaki, Alexandra, additional, Sternberg, Cora N, additional, Nishiyama, Hiroyuki, additional, Castellano, Daniel, additional, Hussain, Syed, additional, Fléchon, Aude, additional, Bamias, Aristotelis, additional, Yu, Evan Y, additional, van der Heijden, Michiel S, additional, Matsubara, Nobuaki, additional, Alekseev, Boris, additional, Necchi, Andrea, additional, Géczi, Lajos, additional, Ou, Yen-Chuan, additional, Coskun, Hasan Senol, additional, Su, Wen-Pin, additional, Hegemann, Miriam, additional, Percent, Ivor J, additional, Lee, Jae-Lyun, additional, Tucci, Marcello, additional, Semenov, Andrey, additional, Laestadius, Fredrik, additional, Peer, Avivit, additional, Tortora, Giampaolo, additional, Safina, Sufia, additional, del Muro, Xavier Garcia, additional, Rodriguez-Vida, Alejo, additional, Cicin, Irfan, additional, Harputluoglu, Hakan, additional, Widau, Ryan C, additional, Liepa, Astra M, additional, Walgren, Richard A, additional, Hamid, Oday, additional, Zimmermann, Annamaria H, additional, Bell-McGuinn, Katherine M, additional, Powles, Thomas, additional, Wong, Suet-Lai Shirley, additional, Tan, Thean Hsiang, additional, Hovey, Elizabeth Jane, additional, Clay, Timothy Dudley, additional, Ng, Siobhan Su Wan, additional, Rutten, Annemie, additional, Machiels, Jean-Pascal, additional, Dumez, Herlinde, additional, Cheng, Susanna Yee-Shan, additional, Chi, Kim Nguyen, additional, Ferrario, Cristiano, additional, Sengeloev, Lisa, additional, Jensen, Niels Viggo, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Flechon, Aude, additional, Culine, Stéphane, additional, Becht, Catherine, additional, Niegisch, Günter, additional, Stöckle, Michael, additional, Grimm, Marc-Oliver, additional, Gakis, Georgios, additional, Schultze-Seemann, Wolfgang, additional, Kalofonos, Haralambos, additional, Mavroudis, Dimitrios, additional, Papandreou, Christos, additional, Karavasilis, Vasilis, additional, Révész, Janos, additional, Geczi, Lajos, additional, Rosenbaum, Eli, additional, Leibowitz-Amit, Raya, additional, Kejzman, Daniel, additional, Sarid, David, additional, Scagliotti, Giorgio Vittorio, additional, Bracarda, Sergio, additional, Massari, Francesco, additional, Osawa, Takahiro, additional, Miyajima, Naoto, additional, Shinohara, Nobuo, additional, Fukuta, Fumimasa, additional, Ohyama, Chikara, additional, Obara, Wataru, additional, Yamashita, Shinichi, additional, Tomita, Yoshihiko, additional, Kawai, Koji, additional, Fukasawa, Satoshi, additional, Oyama, Masafumi, additional, Yonese, Junji, additional, Nagata, Masayoshi, additional, Uemura, Motohide, additional, Nishimura, Kazuo, additional, Kawakita, Mutsushi, additional, Tsunemori, Hiroyuki, additional, Hashine, Katsuyoshi, additional, Inokuchi, Junichi, additional, Yokomizo, Akira, additional, Nagamori, Satoshi, additional, Lee, Hyo Jin, additional, Park, Se Hoon, additional, Rha, Sun Young, additional, Kim, Yu Jung, additional, Lee, Yun-Gyoo, additional, Cortés, Leticia Vazquez, additional, Flores, Claudia Lorena Urzua, additional, Blaisse, Reinoud J B, additional, Erdkamp, Fransiscus L G, additional, Aarts, Maureen J B, additional, Wojcik-Tomaszewska, Joanna, additional, Tomczak, Piotr, additional, Sikora-Kupis, Bozena, additional, Schenker, Michael, additional, Herzal, Alina Amalia, additional, Udrea, Anghel Adrian, additional, Karlov, Petr, additional, Safina, Sufia Z, additional, Fomkin, Roman, additional, Pulido, Enrique Grande, additional, Del Muro, F Xavier García, additional, Mignorance, Juan Ignacio Delgado, additional, Gauna, Daniel Castellano, additional, Rodríguez-Vida, Alejo, additional, Su, Yu-Li, additional, Lin, Chien-Liang, additional, Lin, Chia-Chi, additional, Yeh, Su-Peng, additional, Çiçin, Irfan, additional, Erman, Mustafa, additional, Urun, Yuksel, additional, Golovko, Yurii, additional, Bondarenko, Igor, additional, Sinielnikov, Ivan, additional, Crabb, Simon, additional, Syndikus, Isabel, additional, Huddart, Robert, additional, Sundar, Santhanam, additional, Chowdhury, Simon, additional, Sarwar, Naveed, additional, Flaig, Thomas, additional, Pan, Chong Xian, additional, Petrylak, Daniel, additional, Schwarz, James, additional, Percent, Ivor, additional, Cultrera, Jennifer, additional, Hainsworth, John, additional, Herms, Benjamin, additional, Lawler, William, additional, Lowe, Thomas, additional, Tagawa, Scott, additional, Aragon-Ching, Jeanny, additional, and Vaishampayan, Ulka, additional

Published
2017
Full Text
View/download PDF

163. Molecular markers of paragangliomas/pheochromocytomas

Author

Zhikrivetskaya, Svetlana O., primary, Snezhkina, Anastasiya V., additional, Zaretsky, Andrew R., additional, Alekseev, Boris Y., additional, Pokrovsky, Anatoly V., additional, Golovyuk, Alexander L., additional, Melnikova, Nataliya V., additional, Stepanov, Oleg A., additional, Kalinin, Dmitry V., additional, Moskalev, Alexey A., additional, Krasnov, George S., additional, Dmitriev, Alexey A., additional, and Kudryavtseva, Anna V., additional

Published
2017
Full Text
View/download PDF

165. Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer

Author

Snezhkina, Anastasiya Vladimirovna, primary, Krasnov, George Sergeevich, additional, Zaretsky, Andrew Rostislavovich, additional, Zhavoronkov, Alex, additional, Nyushko, Kirill Mikhailovich, additional, Moskalev, Alexey Alexandrovich, additional, Karpova, Irina Yurievna, additional, Afremova, Anastasiya Isaevna, additional, Lipatova, Anastasiya Valerievna, additional, Kochetkov, Dmitriy Vladimitovich, additional, Fedorova, Maria Sergeena, additional, Volchenko, Nadezhda Nikolaevna, additional, Sadritdinova, Asiya Fayazovna, additional, Melnikova, Nataliya Vladimirovna, additional, Sidorov, Dmitry Vladimirovich, additional, Popov, Anatoly Yurievich, additional, Kalinin, Dmitry Valerievich, additional, Kaprin, Andrey Dmitrievich, additional, Alekseev, Boris Yakovlevich, additional, Dmitriev, Alexey Alexandrovich, additional, and Kudryavtseva, Anna Viktorovna, additional

Published
2016
Full Text
View/download PDF

166. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells

Author

Kudryavtseva, Anna V., primary, Fedorova, Maria S., additional, Zhavoronkov, Alex, additional, Moskalev, Alexey A., additional, Zasedatelev, Alexander S., additional, Dmitriev, Alexey A., additional, Sadritdinova, Asiya F., additional, Karpova, Irina Y., additional, Nyushko, Kirill M., additional, Kalinin, Dmitry V., additional, Volchenko, Nadezhda N., additional, Melnikova, Nataliya V., additional, Klimina, Kseniya M., additional, Sidorov, Dmitry V., additional, Popov, Anatoly Y., additional, Nasedkina, Tatiana V., additional, Kaprin, Andrey D., additional, Alekseev, Boris Y., additional, Krasnov, George S., additional, and Snezhkina, Anastasiya V., additional

Published
2016
Full Text
View/download PDF

169. Mitochondrial dysfunction and oxidative stress in aging and cancer

Author

Kudryavtseva, Anna V., primary, Krasnov, George S., additional, Dmitriev, Alexey A., additional, Alekseev, Boris Y., additional, Kardymon, Olga L., additional, Sadritdinova, Asiya F., additional, Fedorova, Maria S., additional, Pokrovsky, Anatoly V., additional, Melnikova, Nataliya V., additional, Kaprin, Andrey D., additional, Moskalev, Alexey A., additional, and Snezhkina, Anastasiya V., additional

Published
2016
Full Text
View/download PDF

170. Important molecular genetic markers of colorectal cancer

Author

Kudryavtseva, Anna V., primary, Lipatova, Anastasia V., additional, Zaretsky, Andrew R., additional, Moskalev, Alexey A., additional, Fedorova, Maria S., additional, Rasskazova, Anastasiya S., additional, Shibukhova, Galina A., additional, Snezhkina, Anastasiya V., additional, Kaprin, Andrey D., additional, Alekseev, Boris Y., additional, Dmitriev, Alexey A., additional, and Krasnov, George S., additional

Published
2016
Full Text
View/download PDF

171. MiRImpact, a new bioinformatic method using complete microRNA expression profiles to assess their overall influence on the activity of intracellular molecular pathways

Author

Artcibasova, Alina V., primary, Korzinkin, Mikhail B., additional, Sorokin, Maksim I., additional, Shegay, Peter V., additional, Zhavoronkov, Alex A., additional, Gaifullin, Nurshat, additional, Alekseev, Boris Y., additional, Vorobyev, Nikolay V., additional, Kuzmin, Denis V., additional, Kaprin, Аndrey D., additional, Borisov, Nikolay M., additional, and Buzdin, Anton A., additional

Published
2016
Full Text
View/download PDF

172. RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.

Author

Cosgriff, Thomas, primary, Yang, Lin, additional, Alyasova, Anna, additional, Ye, Dingwei, additional, Karpenko, Andrey, additional, Li, Hanzhong, additional, Alekseev, Boris, additional, Xie, Li-ping, additional, Kowalyszyn, Ruben Dario, additional, Karyakin, Oleg, additional, Neron, Yeni Verónica, additional, Collins, LaTonya, additional, Brechenmacher, Thomas, additional, Lin, Chinjune, additional, Morgan, Liza, additional, and Motzer, Robert J., additional

Published
2016
Full Text
View/download PDF

173. RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.

Author

Cosgriff, Thomas, primary, Yang, Lin, additional, Alyasova, Anna, additional, Ye, Dingwei, additional, Karpenko, Andrey, additional, Li, Hanzhong, additional, Alekseev, Boris, additional, Xie, Li-ping, additional, Kowalyszyn, Ruben Dario, additional, Karyakin, Oleg, additional, Neron, Yeni Verónica, additional, Collins, LaTonya, additional, Brechenmacher, Thomas, additional, Lin, Chinjune, additional, Morgan, Liza, additional, and Motzer, Robert J., additional

Published
2016
Full Text
View/download PDF

174. The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβrather than EnterotoxigenicBacteroides fragilisInfection

Author

Snezhkina, Anastasiya V., primary, Krasnov, George S., additional, Lipatova, Anastasiya V., additional, Sadritdinova, Asiya F., additional, Kardymon, Olga L., additional, Fedorova, Maria S., additional, Melnikova, Nataliya V., additional, Stepanov, Oleg A., additional, Zaretsky, Andrew R., additional, Kaprin, Andrey D., additional, Alekseev, Boris Y., additional, Dmitriev, Alexey A., additional, and Kudryavtseva, Anna V., additional

Published
2016
Full Text
View/download PDF

176. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Author

Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dmitry, Pouliot, Frederic, Alekseev, Boris, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor O., Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wu, Sterling, Burgents, Joseph, Molife, L. Rhoda, and Powles, Thomas

Published
2023
Full Text
View/download PDF

178. Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS...

Author

Grande, Enrique, Bamias, Aristotelis, Galsky, Matt D., Kikuchi, Eiji, Davis, Ian D., Arranz, José A., Rezazadeh, Arash, Garcia del Muro, Xavier, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Puente, Javier, Li, Jian-Ri, Lee, Chooi, Bernhard, Sandrine, Nicholas, Alan, Telliez, Julie, and De Santis, Maria

Published
2023
Full Text
View/download PDF

179. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Author

Motzer, Robert J., Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Alekseev, Boris, Rha, Sun Young, Merchan, Jaime R., Goh, Jeffrey C., Kapoor, Anil, De Giorgi, Ugo, Melichar, Bohuslav, Hong, Sung-Hoo, Gurney, Howard, Rodriguez-Lopez, Karla, He, Cixin S., Okpara, Chinyere, McKenzie, Jodi, and Choueiri, Toni K.

Published
2023
Full Text
View/download PDF

180. RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Author

Motzer, Robert, primary, Alyasova, Anna, additional, Ye, Dingwei, additional, Karpenko, Andrey, additional, Li, Hanzhong, additional, Alekseev, Boris Y., additional, Xie, Liping, additional, Kurteva, Galina Petrova, additional, Kowalyszyn, Ruben Dario, additional, Neron, Yeni, additional, Cosgriff, Thomas, additional, Collins, LaTonya, additional, Brechenmacher, Thomas, additional, Segal, Scott, additional, Morgan, Liza M., additional, and Yang, Lin, additional

Published
2015
Full Text
View/download PDF

182. Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis

Author

Dmitriev, Alexey A., primary, Rosenberg, Eugenia E., additional, Krasnov, George S., additional, Gerashchenko, Ganna V., additional, Gordiyuk, Vasily V., additional, Pavlova, Tatiana V., additional, Kudryavtseva, Anna V., additional, Beniaminov, Artemy D., additional, Belova, Anastasia A., additional, Bondarenko, Yuriy N., additional, Danilets, Rostislav O., additional, Glukhov, Alexander I., additional, Kondratov, Aleksandr G., additional, Alexeyenko, Andrey, additional, Alekseev, Boris Y., additional, Klein, George, additional, Senchenko, Vera N., additional, and Kashuba, Vladimir I., additional

Published
2015
Full Text
View/download PDF

184. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways

Author

Lezhnina, Ksenia, Kovalchuk, Olga, Zhavoronkov, Alexander A., Korzinkin, Mikhail B., Zabolotneva, Anastasia A., Shegay, Peter V., Sokov, Dmitry G., Gaifullin, Nurshat M., Rusakov, Igor G., Aliper, Alexander M., Roumiantsev, Sergey A., Alekseev, Boris Y., Borisov, Nikolay M., Buzdin, Anton A., Lezhnina, Ksenia, Kovalchuk, Olga, Zhavoronkov, Alexander A., Korzinkin, Mikhail B., Zabolotneva, Anastasia A., Shegay, Peter V., Sokov, Dmitry G., Gaifullin, Nurshat M., Rusakov, Igor G., Aliper, Alexander M., Roumiantsev, Sergey A., Alekseev, Boris Y., Borisov, Nikolay M., and Buzdin, Anton A.

Abstract

We recently proposed a new bioinformatic algorithm called OncoFinder for quantifying the activation of intracellular signaling pathways. It was proved advantageous for minimizing errors of high-throughput gene expression analyses and showed strong potential for identifying new biomarkers. Here, for the first time, we applied OncoFinder for normal and cancerous tissues of the human bladder to identify biomarkers of bladder cancer. Using Illumina HT12v4 microarrays, we profiled gene expression in 17 cancer and seven non-cancerous bladder tissue samples. These experiments were done in two independent laboratories located in Russia and Canada. We calculated pathway activation strength values for the investigated transcriptomes and identified signaling pathways that were regulated differently in bladder cancer (BC) tissues compared with normal controls. We found, for both experimental datasets, 44 signaling pathways that serve as excellent new biomarkers of BC, supported by high area under the curve (AUC) values. We conclude that the OncoFinder approach is highly efficient in finding new biomarkers for cancer. These markers are mathematical functions involving multiple gene products, which distinguishes them from “traditional” expression biomarkers that only assess concentrations of single genes.

Published
2014

185. Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.

Author

Vladimirovna Snezhkina, Anastasiya, Sergeevich Krasnov, George, Rostislavovich Zaretsky, Andrew, Zhavoronkov, Alex, Mikhailovich Nyushko, Kirill, Alexandrovich Moskalev, Alexey, Yurievna Karpova, Irina, Isaevna Afremova, Anastasiya, Valerievna Lipatova, Anastasiya, Vladimitovich Kochetkov, Dmitriy, Sergeena Fedorova, Maria, Nikolaevna Volchenko, Nadezhda, Fayazovna Sadritdinova, Asiya, Vladimirovna Melnikova, Nataliya, Vladimirovich Sidorov, Dmitry, Yurievich Popov, Anatoly, Valerievich Kalinin, Dmitry, Dmitrievich Kaprin, Andrey, Yakovlevich Alekseev, Boris, and Alexandrovich Dmitriev, Alexey

Subjects
COLON cancer, STOMACH tumors, TUMOR suppressor genes, ENERGY metabolism, OXIDATIVE stress
Abstract

Background: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. CRC molecular pathogenesis is heterogeneous and may be followed by mutations in oncogenes and tumor suppressor genes, chromosomal and microsatellite instability, alternative splicing alterations, hypermethylation of CpG islands, oxidative stress, impairment of different signaling pathways and energy metabolism. In the present work, we have studied the alterations of alternative splicing patterns of genes related to energy metabolism in CRC. Results: Using CrossHub software, we analyzed The Cancer Genome Atlas (TCGA) RNA-Seq datasets derived from colon tumor and matched normal tissues. The expression of 1014 alternative mRNA isoforms involved in cell energy metabolism was examined. We found 7 genes with differentially expressed alternative transcripts whereas overall expression of these genes was not significantly altered in CRC. A set of 8 differentially expressed transcripts of interest has been validated by qPCR. These eight isoforms encoded by OGDH, COL6A3, ICAM1, PHPT1, PPP2R5D, SLC29A1, and TRIB3 genes were up-regulated in colorectal tumors, and this is in concordance with the bioinformatics data. The alternative transcript NM_057167 of COL6A3 was also strongly up-regulated in breast, lung, prostate, and kidney tumors. Alternative transcript of SLC29A1 (NM_001078177) was up-regulated only in CRC samples, but not in the other tested tumor types. Conclusions: We identified tumor-specific expression of alternative spliced transcripts of seven genes involved in energy metabolism in CRC. Our results bring new knowledge on alternative splicing in colorectal cancer and suggest a set of mRNA isoforms that could be used for cancer diagnosis and development of treatment methods. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

186. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways

Author

Lezhnina, Ksenia, primary, Kovalchuk, Olga, additional, Zhavoronkov, Alexander A., additional, Korzinkin, Mikhail B., additional, Zabolotneva, Anastasia A., additional, Shegay, Peter V., additional, Sokov, Dmitry G., additional, Gaifullin, Nurshat M., additional, Rusakov, Igor G., additional, Aliper, Alexander M., additional, Roumiantsev, Sergey A., additional, Alekseev, Boris Y., additional, Borisov, Nikolay M., additional, and Buzdin, Anton A., additional

Published
2014
Full Text
View/download PDF

187. A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to histopathology: An interim analysis.

Author

Slawin, Kevin Mark, primary, Tenke, Peter, additional, Joniau, Steven, additional, Ellis, William J., additional, Alekseev, Boris Y., additional, Buzogány, Istvan, additional, Mishugin, Sergey, additional, Klein, Eric A., additional, Stolz, Josef, additional, Student, Vladimir, additional, Matveev, Vsevolod, additional, Karnes, R. Jeffrey, additional, Jarrard, David Frasier, additional, Yuh, Bertram E., additional, Scherr, Douglas, additional, Trabulsi, Edouard John, additional, Babich, John, additional, Stambler, Nancy, additional, Armor, Thomas, additional, and Israel, Robert Joseph, additional

Published
2014
Full Text
View/download PDF

189. A phase II study of 99mTc-trofolastat (MIP-1404) SPECT/CT to identify and localize prostate cancer in high-risk patients undergoing radical prostatectomy (RP) and extended pelvic lymph node dissection (EPLND) compared to histopathology: An interim analysis.

Author

Slawin, Kevin Mark, primary, Ellis, William J., additional, Tenke, Peter, additional, Joniau, Steven, additional, Alekseev, Boris Y., additional, Buzogány, Istvan, additional, Mishugin, Sergey, additional, Klein, Eric A., additional, Karnes, R. Jeffrey, additional, Scherr, Douglas, additional, Yuh, Bertram E., additional, Jarrard, David Frasier, additional, Trabulsi, Edouard John, additional, Stolz, Josef, additional, Babich, John, additional, Youssoufian, Hagop, additional, Stambler, Nancy, additional, Armor, Thomas, additional, and Israel, Robert Joseph, additional

Published
2014
Full Text
View/download PDF

190. Epigenetic Alterations of Chromosome 3 Revealed by NotI-Microarrays in Clear Cell Renal Cell Carcinoma

Author

Dmitriev, Alexey A., primary, Rudenko, Evgeniya E., additional, Kudryavtseva, Anna V., additional, Krasnov, George S., additional, Gordiyuk, Vasily V., additional, Melnikova, Nataliya V., additional, Stakhovsky, Eduard O., additional, Kononenko, Oleksii A., additional, Pavlova, Larissa S., additional, Kondratieva, Tatiana T., additional, Alekseev, Boris Y., additional, Braga, Eleonora A., additional, Senchenko, Vera N., additional, and Kashuba, Vladimir I., additional

Published
2014
Full Text
View/download PDF

191. Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

Author

Motzer, Robert J., primary, Nosov, Dmitry, additional, Eisen, Timothy, additional, Bondarenko, Igor, additional, Lesovoy, Vladimir, additional, Lipatov, Oleg, additional, Tomczak, Piotr, additional, Lyulko, Oleksiy, additional, Alyasova, Anna, additional, Harza, Mihai, additional, Kogan, Mikhail, additional, Alekseev, Boris Y., additional, Sternberg, Cora N., additional, Szczylik, Cezary, additional, Cella, David, additional, Ivanescu, Cristina, additional, Krivoshik, Andrew, additional, Strahs, Andrew, additional, Esteves, Brooke, additional, Berkenblit, Anna, additional, and Hutson, Thomas E., additional

Published
2013
Full Text
View/download PDF

192. Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.

Author

Ravaud, Alain, primary, Barrios, Carlos H., additional, Alekseev, Boris Y., additional, Tay, Miah Hiang, additional, Agarwala, Sanjiv S., additional, Yalcin, Suayib, additional, Lin, Chia-Chi, additional, Shkolnik, Michail, additional, Matveev, Vsevolod, additional, Anak, Ozlem, additional, Gogov, Sven, additional, Pelov, Diana, additional, Louveau, Anne-Laure, additional, Vaury, Alexandra, additional, and Melichar, Bohuslav, additional

Published
2013
Full Text
View/download PDF

193. PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

Author

Eisenberger, Mario A., primary, Hardy-Bessard, Anne-Claire, additional, Ford, Daniel, additional, Mourey, Loic, additional, Parente, Phillip, additional, Mainwaring, Paul N., additional, Ng, Siobhan, additional, Alekseev, Boris, additional, Matveev, Vsevolod, additional, Carles, Joan, additional, Shapiro, Jeremy, additional, Latorzeff, Igor, additional, Bodrogi, Istvan, additional, Kim, Choung-Soo, additional, Font, Albert, additional, Segal, Roanne, additional, Berg, Hendrik Pieter Van Den, additional, Zhang, Wenping (Wendy), additional, Chadjaa, Mustapha, additional, and De Bono, Johann Sebastian, additional

Published
2013
Full Text
View/download PDF

195. The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis Infection.

Author

Snezhkina, Anastasiya V., Krasnov, George S., Lipatova, Anastasiya V., Sadritdinova, Asiya F., Kardymon, Olga L., Fedorova, Maria S., Melnikova, Nataliya V., Stepanov, Oleg A., Zaretsky, Andrew R., Kaprin, Andrey D., Alekseev, Boris Y., Dmitriev, Alexey A., and Kudryavtseva, Anna V.

Published
2016
Full Text
View/download PDF

196. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Author

Pienta, Kenneth J., primary, Machiels, Jean-Pascal, additional, Schrijvers, Dirk, additional, Alekseev, Boris, additional, Shkolnik, Mikhail, additional, Crabb, Simon J., additional, Li, Susan, additional, Seetharam, Shobha, additional, Puchalski, Thomas A., additional, Takimoto, Chris, additional, Elsayed, Yusri, additional, Dawkins, Fitzroy, additional, and de Bono, Johann S., additional

Published
2012
Full Text
View/download PDF

197. Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.

Author

Eisenberger, Mario A., primary, Hardy-Bessard, Anne-Claire, additional, Mourey, Loic, additional, Mainwaring, Paul N., additional, Ford, Daniel, additional, Shapiro, Jeremy David, additional, Carles, Joan, additional, Ng, Siobhan, additional, Gil, Thierry, additional, Alekseev, Boris, additional, Ivanov, Sergey, additional, Facchini, Thomas, additional, Legouffe, Eric, additional, Apolikhin, Oleg, additional, Pandha, Hardev S., additional, Beeker, Aart, additional, Karyakin, Oleg, additional, Zhang, Wendy, additional, Chadjaa, Mustapha, additional, and De Bono, Johann Sebastian, additional

Published
2012
Full Text
View/download PDF

199. Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer

Author

S. Mikhaylenko, Dmitry, D. Efremov, Gennady, V. Strelnikov, Vladimir, V. Zaletaev, Dmitry, and Y. Alekseev, Boris

Abstract

Prostate cancer (PC) is the most common uro-oncological disease in the global population and still requires a more efficient laboratory diagnosis. Point mutations of oncogenes and tumor suppressor genes are the most frequent molecular genetic events in carcinogenesis. The mutations are responsible, to a great extent, for the clonal evolution of cancer and can be considered as primary candidate molecular markers of PC. Using next-generation sequencing to analyze the mutations in PC, the main molecular PC subtypes were identified, which depended on the presence of fusion genes and FOXA1, CHD1, and SPOP point mutations; other driver mutations responsible for the progression of PC subclones were also characterized. This review summarizes the data on early PC genetic markers (an mtDNA deletion, and TMPRSS2:ERG expression), as well as these somatic mutations at later stages of PC. Emphasis is placed on a switch in AR synthesis to a constitutively active variant and the point mutations that facilitate PC transition to a castration-refractory state that is resistant to new AR inhibitors. Based on the current whole-exome sequencing data, the frequencies and localizations of the somatic mutations that may provide new genetic diagnostic markers and drug targets are described.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results